OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialActive

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

A phase 3 trial of Acalabrutinib, Prednisone, Rituximab in diffuse large b-cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.